Mari Aso

522 total citations
11 papers, 346 citations indexed

About

Mari Aso is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Mari Aso has authored 11 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Mari Aso's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Mari Aso is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Mari Aso collaborates with scholars based in Japan. Mari Aso's co-authors include Yukihiro Toi, Yuichiro Kimura, Yoshihiro Honda, Kyoji Tsurumi, Yosuke Kawashima, Hisashi Shimizu, Jun Sugisaka, Tomoiki Aiba, Ryohei Saito and Shunichi Sugawara and has published in prestigious journals such as Annals of Oncology, The Oncologist and Cancer Science.

In The Last Decade

Mari Aso

10 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mari Aso Japan 6 304 127 74 41 35 11 346
Yutaka Domeki Japan 6 491 1.6× 229 1.8× 103 1.4× 40 1.0× 47 1.3× 10 529
Keisuke Terayama Japan 6 491 1.6× 230 1.8× 103 1.4× 40 1.0× 47 1.3× 10 531
Kyoji Tsurumi Japan 6 492 1.6× 232 1.8× 103 1.4× 40 1.0× 47 1.3× 11 531
Tomoiki Aiba Japan 7 496 1.6× 235 1.9× 107 1.4× 40 1.0× 49 1.4× 18 544
John A. Kosteva United States 6 435 1.4× 204 1.6× 77 1.0× 19 0.5× 18 0.5× 12 496
Yael Steinberg‐Silman Israel 7 307 1.0× 56 0.4× 74 1.0× 48 1.2× 38 1.1× 8 373
Arissa Young United States 7 214 0.7× 57 0.4× 84 1.1× 40 1.0× 40 1.1× 10 332
Gregory S. Phillips United States 6 325 1.1× 59 0.5× 95 1.3× 71 1.7× 41 1.2× 7 479
S. Le Burel France 4 263 0.9× 58 0.5× 59 0.8× 29 0.7× 114 3.3× 7 344
Marie-Léa Gauci France 8 257 0.8× 57 0.4× 88 1.2× 67 1.6× 23 0.7× 12 342

Countries citing papers authored by Mari Aso

Since Specialization
Citations

This map shows the geographic impact of Mari Aso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mari Aso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mari Aso more than expected).

Fields of papers citing papers by Mari Aso

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mari Aso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mari Aso. The network helps show where Mari Aso may publish in the future.

Co-authorship network of co-authors of Mari Aso

This figure shows the co-authorship network connecting the top 25 collaborators of Mari Aso. A scholar is included among the top collaborators of Mari Aso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mari Aso. Mari Aso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Aso, Mari, et al.. (2023). Nivolumab Therapy in Lung Cancer Associated with IgG4-related Disease. Internal Medicine. 63(2). 283–287. 3 indexed citations
2.
3.
Ota, Hiroki, et al.. (2023). Transbronchial cryobiopsy using an ultrathin cryoprobe with a guide sheath for the diagnosis of pulmonary mucosa-associated lymphoid tissue lymphoma. Journal of Thoracic Disease. 15(12). 7123–7129. 1 indexed citations
4.
Mizugaki, Hidenori, Ryo Morita, Kazunari Tateishi, et al.. (2022). Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression. Cancer Science. 113(6). 2109–2117. 5 indexed citations
5.
Yamaguchi, Yoshitaka, Mari Aso, Hikaru Nagasawa, & Manabu Wada. (2021). Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma. Internal Medicine. 60(18). 3025–3029. 11 indexed citations
6.
Toi, Yukihiro, Yuichiro Kimura, Yutaka Domeki, et al.. (2019). Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.. PubMed Central. 36(1). 74–78. 6 indexed citations
7.
Toi, Yukihiro, Shunichi Sugawara, Mari Aso, et al.. (2019). P1.16-29 Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S598–S599. 1 indexed citations
8.
Aso, Mari, Yukihiro Toi, Jun Sugisaka, et al.. (2019). Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. The Oncologist. 25(3). e536–e544. 46 indexed citations
9.
10.
Sugisaka, Jun, Shunichi Sugawara, Yukihiro Toi, et al.. (2019). Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world. Annals of Oncology. 30. ix112–ix113. 2 indexed citations
11.
Toi, Yukihiro, Shunichi Sugawara, Jun Sugisaka, et al.. (2018). Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 5(3). 376–376. 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yutaka Domeki Breakdown of academic impact, for papers by Keisuke Terayama Breakdown of academic impact, for papers by Kyoji Tsurumi Breakdown of academic impact, for papers by Tomoiki Aiba Breakdown of academic impact, for papers by John A. Kosteva Breakdown of academic impact, for papers by Yael Steinberg‐Silman Breakdown of academic impact, for papers by Arissa Young Breakdown of academic impact, for papers by Gregory S. Phillips Breakdown of academic impact, for papers by S. Le Burel Breakdown of academic impact, for papers by Marie-Léa Gauci
Rankless by CCL
2026